Nattokinase Uses
Nattokinase is a fibrinolytic enzyme derived from fermented soybeans (natto) that shows promise for cardiovascular health, particularly in managing atherosclerosis, hyperlipidemia, and hypertension, though it lacks FDA approval and formal guideline endorsement for any medical indication.
Evidence-Based Applications
Cardiovascular Disease Management
Atherosclerosis and Lipid Control
- Effective dose: 10,800 FU/day for managing atherosclerosis progression and hyperlipidemia 1
- At this dose, nattokinase significantly reduces:
- Carotid artery intima-media thickness
- Carotid plaque size (improvement rates 66.5-95.4%)
- Total cholesterol, LDL cholesterol, and triglycerides 1
Critical caveat: Lower doses (3,600 FU/day) are ineffective for lipid-lowering and atherosclerosis management 1. This directly contradicts commonly recommended doses of 2,000 FU/day found in commercial products.
Blood Pressure Reduction
- Meta-analysis demonstrates significant reductions in:
- Systolic BP: -3.45 mmHg (95% CI: -4.37 to -2.18)
- Diastolic BP: -2.32 mmHg (95% CI: -2.72 to -1.92) 2
Thrombolytic Properties
Nattokinase functions as a serine protease with direct fibrinolytic activity, dissolving blood clots through enzymatic degradation of fibrin 3, 4. However, no clinical guidelines recommend nattokinase as a substitute for established thrombolytic agents (streptokinase, urokinase, tPA) in acute thrombotic emergencies 5, 6, 5.
The enzyme's activity is heat-sensitive and requires intact enzymatic function—heat-inactivated nattokinase loses all therapeutic effects 4.
Neuroprotective Effects
Emerging evidence suggests potential benefits in:
- Ischemic stroke models: Dose-dependent reduction in infarction volume and neurological symptoms (5,000-20,000 FU/kg in animal studies) 4
- Cognitive function: Possible selective improvement in visuospatial function in patients with asymptomatic intracranial/carotid stenosis (8,000 FU/day for 6 months), though global cognition unchanged 7
- Blood-brain barrier protection: Preclinical evidence for reducing BBB dysfunction in neurodegenerative disorders 8
Other Applications
- Dental health: Reduces mutacin activity in Streptococcus mutans at 1 mg/mL, potentially preventing dental caries 9
- Anti-inflammatory effects: Reduces proinflammatory cytokines and oxidative stress markers 4
Mechanisms of Action
Nattokinase works through multiple pathways:
- Direct fibrinolysis: Enzymatic breakdown of fibrin clots
- Lipid metabolism: Activates hormone-sensitive lipase, inhibits HMG-CoA reductase, enhances lipoprotein lipase activity 10
- Vascular function: Improves endothelial function and blood flow
- Anti-inflammatory: Reduces ROS and inflammatory cytokines 4
Dosing Considerations
For cardiovascular benefits 1:
- Effective dose: 10,800 FU/day
- Duration: Minimum 12 months for atherosclerosis management
- Lower doses (<3,600 FU/day) are ineffective
Enhanced efficacy with:
- Co-administration of vitamin K2 and aspirin (synergistic effects)
- Regular exercise
- Higher BMI, smoking, or alcohol consumption (paradoxically shows greater lipid-lowering response)
Safety Profile
- Well-tolerated with no notable adverse effects in clinical trials up to 12 months 1
- Contraindication: Patients on anticoagulants or with bleeding disorders (theoretical increased bleeding risk, though not documented in trials)
- Caution: Avoid heat exposure during storage—destroys enzymatic activity 4
- No significant drug interactions reported, though theoretical concerns exist with antiplatelet agents
Critical Limitations
Nattokinase is NOT a substitute for:
- FDA-approved thrombolytics (tPA, streptokinase, urokinase) in acute thrombotic emergencies 5, 6, 5
- Statins or fibrates in established cardiovascular disease requiring guideline-directed medical therapy 11
- Anticoagulation in conditions requiring therapeutic anticoagulation (prosthetic valves, atrial fibrillation) 5
Evidence gaps:
- No large-scale randomized controlled trials comparing nattokinase to standard cardiovascular therapies
- No guideline endorsement from major cardiovascular societies (AHA, ACC, ESC)
- Optimal dosing and duration remain incompletely defined
- Long-term safety data beyond 12 months lacking
Clinical Application Algorithm
For patients considering nattokinase:
Primary prevention of cardiovascular disease with mild hyperlipidemia or hypertension:
- Consider 10,800 FU/day if patient refuses or is intolerant to statins/antihypertensives
- Monitor lipid panel and blood pressure at 3 and 6 months
- Discontinue if no improvement after 6 months
Adjunctive therapy in established cardiovascular disease:
- May add to statin therapy for additional lipid-lowering
- Continue guideline-directed medical therapy
- Consider co-administration with vitamin K2 for synergistic effects
NOT recommended:
- Acute thrombotic events (stroke, MI, DVT, PE)
- Replacement for anticoagulation in atrial fibrillation or prosthetic valves
- Patients with active bleeding or bleeding disorders
Product selection: Choose preparations with verified potency (FU/dose clearly labeled), avoid heat-exposed products, and ensure pharmaceutical-grade quality given lack of FDA regulation.